359 related articles for article (PubMed ID: 20520598)
1. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.
Nielsen J; Skadhede S; Correll CU
Neuropsychopharmacology; 2010 Aug; 35(9):1997-2004. PubMed ID: 20520598
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Gianfrancesco FD; Grogg AL; Mahmoud RA; Wang RH; Nasrallah HA
J Clin Psychiatry; 2002 Oct; 63(10):920-30. PubMed ID: 12416602
[TBL] [Abstract][Full Text] [Related]
4. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.
Gianfrancesco F; Grogg A; Mahmoud R; Wang RH; Meletiche D
Clin Ther; 2003 Apr; 25(4):1150-71. PubMed ID: 12809963
[TBL] [Abstract][Full Text] [Related]
6. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
7. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
Ollendorf DA; Joyce AT; Rucker M
MedGenMed; 2004 Jan; 6(1):5. PubMed ID: 15208518
[TBL] [Abstract][Full Text] [Related]
8. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis.
Bloechliger M; Rüegg S; Jick SS; Meier CR; Bodmer M
CNS Drugs; 2015 Jul; 29(7):591-603. PubMed ID: 26242478
[TBL] [Abstract][Full Text] [Related]
10. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis.
Galling B; Roldán A; Nielsen RE; Nielsen J; Gerhard T; Carbon M; Stubbs B; Vancampfort D; De Hert M; Olfson M; Kahl KG; Martin A; Guo JJ; Lane HY; Sung FC; Liao CH; Arango C; Correll CU
JAMA Psychiatry; 2016 Mar; 73(3):247-59. PubMed ID: 26792761
[TBL] [Abstract][Full Text] [Related]
11. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.
Woerner MG; Correll CU; Alvir JM; Greenwald B; Delman H; Kane JM
Neuropsychopharmacology; 2011 Jul; 36(8):1738-46. PubMed ID: 21508932
[TBL] [Abstract][Full Text] [Related]
12. [Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].
Rubio G; Gómez-de-la-Cámara A; Ledesma F; Burón JA; Rodríguez-Morales A; Martínez-Junquera G;
Med Clin (Barc); 2006 Apr; 126(12):441-4. PubMed ID: 16620729
[TBL] [Abstract][Full Text] [Related]
13. Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study.
Rajkumar AP; Horsdal HT; Wimberley T; Cohen D; Mors O; Børglum AD; Gasse C
Am J Psychiatry; 2017 Jul; 174(7):686-694. PubMed ID: 28103712
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
15. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.
Lund BC; Perry PJ; Brooks JM; Arndt S
Arch Gen Psychiatry; 2001 Dec; 58(12):1172-6. PubMed ID: 11735847
[TBL] [Abstract][Full Text] [Related]
16. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
[TBL] [Abstract][Full Text] [Related]
17. What evidence is there to show which antipsychotics are more diabetogenic than others?
Jesus C; Jesus I; Agius M
Psychiatr Danub; 2015 Sep; 27 Suppl 1():S423-8. PubMed ID: 26417808
[TBL] [Abstract][Full Text] [Related]
18. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
19. Safety outcomes of antipsychotics classes in drug-naïve patients with first-episode schizophrenia: A nationwide cohort study in South Korea.
Lee DY; Kim C; Yu DH; Park RW
Asian J Psychiatr; 2024 Jan; 91():103857. PubMed ID: 38128353
[TBL] [Abstract][Full Text] [Related]
20. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
